STAT Plus: A biotech startup hopes to disarm cancer by targeting a genetic bandolier
ALEX HOGAN/STAT
The company, Boundless, traces its roots to the discovery that extrachromosomal DNA is far more common in cancer cells than previously thought.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario